Immunoglobin G / total antibody testing for SARS-CoV-2: a prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing 3 commercial tests

Coronavirus disease (COVID-19) is interfering heavily with the screening, diagnosis and treatment of cancer patients. Better knowledge of the seroprevalence and immune response after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in this population is important to manage them safely during the pandemic.

Source: European Journal of Cancer - February 27, 2021 Category: Cancer & Oncology Authors: Peter van Dam, Manon Huizing, Ella Roelant, An Hotterbeekx, Fien HR. De Winter, Samir Kumar-Singh, Pieter Moons, Zainab Amajoud, Christof Vulsteke, Lieselot Croes, Annelies Janssens, Zwi Berneman, Hans Prenen, Leander Meuris, Wim Vanden Berghe, Evelien Sm Tags: Original Research Source Type: research